Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | ALB | P02768 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13464208 | 1.00 | TSHR (0.32) | TSHRALBPOLBHSD17B10HPGD | |
| SCHEMBL13464206 | 0.84 | ALB (0.42) | ALB | |
| SCHEMBL13445975 | 0.84 | ALB (0.42) | ALB | |
| SCHEMBL22389051 | 0.84 | SMN1; SMN2 (0.39) | TSHRALBPOLBHSD17B10HPGD | |
| SCHEMBL13446006 | 0.82 | ALB (0.35) | ALB | |
| SCHEMBL30232609 | 0.79 | TAS1R3 (0.37) | POLBHPGD | |
| SCHEMBL28712809 | 0.76 | HPGD (0.38) | TSHRPOLBHPGDHTTSMN1; SMN2 | |
| SCHEMBL22688008 | 0.76 | HPGD (0.38) | TSHRPOLBHPGDHTTSMN1; SMN2 | |
| SCHEMBL20346566 | 0.76 | TDP1 (0.40) | POLB | |
| SCHEMBL15502875 | 0.75 | NAAA (0.38) | ALBPOLBHPGDHTTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2288388-B1 | ACHIEVEMENT OF HIGH THERAPEUTIC INDEX THROUGH MOLECULAR IMAGING GUIDED TARGETED DRUG TREATMENT | SIEMENS MEDICAL SOLUTIONS (US) | 2016-08-31 | — | — | EP | disclosed |
| US-8293206-B2 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2012-10-23 | — | — | US | disclosed |
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100074910-A1 | Achievement of a high therapeutic index through molecular imaging guided targeted drug treatment | MKI67, CD47, CD68 | TSHR 3656/4885ALB 237/4885POLB 2050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.